A genetically influenced protein called lipoprotein(a), or Lp(a), plays a key role in raising the risk of both atherosclerotic cardiovascular disease and calcified aortic valve disease. While raised Lp(a) levels correlate with higher cardiovascular risk, standard lipid-lowering medications rarely impact Lp(a) concentrations meaningfully. This has spurred growing interest in developing therapies capable of significantly reducing Lp(a), though concerns persist about possible long-term effects beyond cardiovascular health.
Genetic Analysis of Lp(a) Reduction
A recent study in European Heart Journal Open examined whether naturally lower Lp(a) levels, driven by genetic variations in the LPA gene, might negatively affect reproductive health, pregnancy outcomes, or offspring development. The research aims to clarify safety concerns, as Lp(a) levels are primarily determined by inherited genetic factors. Though high Lp(a) is firmly linked to cardiovascular disease, its broader biological functions remain unclear, leaving uncertainty about whether aggressive Lp(a) reduction, especially during fertile years or pregnancy, could lead to unintended health effects.
Study Design and Results
The researchers employed multiple genetic approaches to assess connections between reduced Lp(a) and reproductive health, including two-sample Mendelian randomization, genetic risk scoring, and gene-based association analyses that accounted for both common and rare LPA gene variants. Data were drawn from 236,228 women in the UK Biobank and 122,038 women in the All of Us research program, integrating genetic sequencing with health records and biomarkers. Additionally, infertility was analyzed among 102,549 women in All of Us.
The study evaluated a range of reproductive and developmental outcomes, such as pregnancy complications, delivery difficulties, congenital abnormalities, and infertility. After adjusting for multiple comparisons, the genetic analyses revealed no statistically significant harmful associations between lower Lp(a) levels and adverse reproductive or offspring health effects. While some initial associations emerged using different genetic methods, these did not withstand statistical correction, suggesting they may have occurred by chance.
Further analysis showed that confidence intervals for fertility-related measures included neutral values, indicating the data did not strongly support any meaningful link between genetically reduced Lp(a) and reproductive issues. Control tests confirmed expected relationships between higher Lp(a) and lipid markers like LDL cholesterol and triglycerides, validating the genetic methods’ biological relevance.
Key Takeaways and Future Directions
However, the lack of significant associations does not definitively prove safety. Genetic studies assess lifelong biological variations, which may differ from the effects of short-term pharmacological Lp(a) reduction. Additionally, rare pregnancy complications or birth defects could still go undetected even in large datasets, particularly when relying on electronic health records. The study also analyzed genetically proxied Lp(a) lowering rather than actual drug exposure, leaving unanswered questions about specific therapies‘ safety during pregnancy, treatment timing around conception, or whether certain patient groups need extra precautions.
